Professional
Added to YB: 2024-12-13
Pitch date: 2024-09-30
NVO [bullish]
Novo Nordisk A/S
-65.17%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 112.61
Price Target
N/A
Dividend
4.56%
EV/EBITDA
7.01
P/E
9.79
EV/Sales
3.73
Sector
Pharmaceuticals
Category
growth
PGIM Jennison Health Sciences Fund Portfolio Holding: Novo Nordisk A/S
NVO: Best-in-class GLP-1 portfolio driving accelerating growth in diabetes & obesity. Underappreciated magnitude & durability of new product inflection. Top 2 fastest-growing biopharma globally. Promising pipeline in NASH & Alzheimer's. 2024 sales guidance raised. Obesity market estimates likely to rise. CagriSema Phase 3 & supply ramp catalysts.
Read full article (2 min)